Immunomodulation and preeclampsia.


Journal

Best practice & research. Clinical obstetrics & gynaecology
ISSN: 1532-1932
Titre abrégé: Best Pract Res Clin Obstet Gynaecol
Pays: Netherlands
ID NLM: 101121582

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 07 03 2019
revised: 10 04 2019
accepted: 17 06 2019
pubmed: 18 7 2019
medline: 18 2 2020
entrez: 18 7 2019
Statut: ppublish

Résumé

Preeclampsia (PE) is an enigmatic syndrome, still with unknown aetiology and multi-factorial pathogenesis. Our understanding of the role of the immune system in PE development has undergone a transformation over the years. From a model based on the alterations in cell-mediated immunity, research moved on to a vision centred on the alteration of the humoural immunity and on the systemic involvement of the inflammatory system. The first hypothesis was classically derived from the evidence that an adequate maternal immunological response is necessary in pregnancy to allow the survival of the foetus. An abnormal response of the maternal immune system against the placenta may be the first pathogenetic step of PE, followed by a systemic inflammatory reaction. Currently available treatments for PE are mainly preventative with aspirin. Treatment aims to modulate inflammation and the immune system before their changes become established.

Identifiants

pubmed: 31311760
pii: S1521-6934(19)30084-7
doi: 10.1016/j.bpobgyn.2019.06.005
pii:
doi:

Substances chimiques

Placenta Growth Factor 144589-93-5

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

87-96

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Marianna Pina Rambaldi (MP)

Obstetrics and Gynecology Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.

Eran Weiner (E)

Department of Obstetrics & Gynecology, the Edith Wolfson Medical Center, Holon, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Federico Mecacci (F)

Obstetrics and Gynecology Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.

Jacob Bar (J)

Department of Obstetrics & Gynecology, the Edith Wolfson Medical Center, Holon, Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Felice Petraglia (F)

Obstetrics and Gynecology Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy. Electronic address: felice.petraglia@unifi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH